archived mechanistic market 0.411
gene:
TH, AADCpathway: Tyrosine hydroxylase / catecholamine synthesisdisease: neurodegenerationEngineered probiotic bacteria expressing tyrosine hydroxylase and aromatic L-amino acid decarboxylase could produce L-DOPA locally in the gut, providing sustained dopamine precursor delivery while bypassing hepatic metabolism and reducing motor fluctuations.
Scores
Composite
0.384
Confidence
0.200
Novelty
0.900
Feasibility
0.100
Impact
0.400
Mechanism
0.300
Druggability
0.200
Safety
0.200
Evidence
For (5)
- Mild/moderate phenotypes in AADC deficiency: Focus on the aromatic amino acid decarboxylase protein. [J Inherit Metab Dis]
- Compound Heterozygosis in AADC Deficiency and Its Complex Phenotype in Terms of AADC Protein Population. [Int J Mol Sci]
- Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons. [Nat Commun]
- A review of aromatic l-amino acid decarboxylase (AADC) deficiency in Taiwan. [Am J Med Genet C Semin Med Genet]
- Blood, urine and cerebrospinal fluid analysis in TH and AADC deficiency and the effect of treatment. [Mol Genet Metab Rep]
Against (2)
- Gut bacteria can metabolize levodopa through an interspecies pathway, implying engineered gut catecholamine precursor production may be degraded or pharmacokinetically unstable. [Science]
- Gut bacterial tyrosine decarboxylases restrict levodopa levels, directly challenging assumptions that intestinal bacterial dopamine-precursor handling is reliably beneficial. [Nat Commun]
Discussion
No comments yet — be the first.